Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
暂无分享,去创建一个
Y. Ohe | K. Kiura | K. Goto | K. Nishio | Y. Nakanishi | A. Zimmermann | M. Nishio | Toshiaki Takahashi | N. Yamamoto | T. Seto | M. Reck | T. Tamura | K. Nakagawa | S. Wijayawardana | E. Garon | K. Sakai | T. Kato | C. Visseren-Grul | Gosuke Homma | R. Hozak | S. Enatsu | B. Frimodt-Moller
[1] J. Shih,et al. Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY , 2020, Cancer science.
[2] J. Cui,et al. Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments , 2020, Journal of Cancer Research and Clinical Oncology.
[3] Joe Y. Chang,et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[4] J. Shih,et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[5] Zhen Yang,et al. Update on liquid biopsy in clinical management of non-small cell lung cancer , 2019, OncoTargets and therapy.
[6] T. Yamanaka,et al. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV , 2019, International Journal of Clinical Oncology.
[7] A. Gemma,et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.
[8] T. Mitsudomi,et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. , 2019, Annals of Oncology.
[9] T. Mitsudomi,et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] S. Vowler,et al. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset , 2018, Japanese journal of clinical oncology.
[11] P. V. Van Schil,et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Shih,et al. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer , 2018, Molecular Cancer.
[13] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[14] D. Rimm,et al. Worldwide Frequency of Commonly Detected EGFR Mutations. , 2017, Archives of pathology & laboratory medicine.
[15] ping wang,et al. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer , 2017, Oncotarget.
[16] M. Ahn,et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.
[17] K. Wang,et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis , 2016, Oncotarget.
[18] J. Yokota,et al. Gene aberrations for precision medicine against lung adenocarcinoma , 2016, Cancer science.
[19] Jing-hao Liu,et al. Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. , 2016, Cancer letters.
[20] K. Nishio,et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples , 2015, Oncotarget.
[21] Fang Wang,et al. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis , 2015, European Journal of Clinical Pharmacology.
[22] Koichi Goto,et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. , 2014, The Lancet. Oncology.
[23] P. Jänne,et al. Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance , 2009, Clinical Cancer Research.
[24] L. Shewchuk,et al. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. , 2008, Cancer research.
[25] L. Byers,et al. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. , 2007, Clinical lung cancer.
[26] K. Yoneda,et al. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. , 2006, Clinical lung cancer.
[27] Stuart Thomson,et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. , 2006, Cancer research.
[28] D. Hicklin,et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. , 2001, Cancer research.